Comparative Study of Different Products of Carbamazepine Tablets Available in Iraqi Market
Abstract
Carbamazepine (CBZ) is a widely used antiepileptic drug to control grand mal epilepsy, as well as for the treatment of peripheral neuralgia. According to the biopharmaceutical classification system (BCS), CBZ is considered a class II drug. CBZ is characterized by a slow and irregular gastrointestinal absorption, with irregular oral bioavailability; due to its low water solubility. Therefore, the release of the drug from the dosage form (tablets in this study) and the subsequent step of dissolution represent the most important parameters that decide whether a sufficient plasma concentration will be achieved or not. In the current study, the FTIR study for the pure API, CBZ, and the different commercially available brands of CBZ conventional tablets, available in the Iraqi drug market (Mosul city as an example), were examined. Subsequently, various quality control parameters such as the weight variation, content uniformity, friability, and hardness of the conventional CBZ tablets were conducted. Moreover, the disintegration and the dissolution tests of the different brands of CBZ available in the Iraqi drug market were performed.
Keywords: Antiepileptic Drug, Bioequivalence; Epilepsy; Generic; Brand vs generic; IVIVC; QC
Keywords:
Antiepileptic Drug, Bioequivalence, Epilepsy, Generic, Brand vs generic, QC, IVIVCDOI
https://doi.org/10.22270/jddt.v11i2-S.4808References
Organization WH. Quality assurance of pharmaceuticals: A compendium of guidelines and related materials. Good manufacturing practices and inspection: World Health Organization; 2007.
Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide. Clinical pharmacokinetics. 1986 Sep; 11(3):177-98.
Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2013 Mar; 18(Suppl 1):S81.
Oluka MO, Mitema ES, Kibwage IO, Kwasa TO, Kokwaro GO. A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market. East African medical journal. 1996 May 1; 73(5):323-6.
Kranz H, Wagner T. Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations. European journal of pharmaceutics and biopharmaceutics. 2006 Jan 1; 62(1):70-6.
USP. United States Pharmacopeia. United States Pharmacopeial; 2015.
Moffat AC, Osselton MD, Widdop B, Watts J. Clarke's analysis of drugs and poisons. London: Pharmaceutical press; 2011.
Fortuna A, Alves G, Soares-da-Silva P, Falcão A. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. Epilepsy research. 2013 Nov 1; 107(1-2):37-50.
Panday DR, Panday KR, Basnet M, Kafle S, Shah B, Rauniar GP. Therapeutic drug monitoring of carbamazepine. Int J Neurorehabilitation Eng. 2017; 4(245):2376-0281.
Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide. Clinical pharmacokinetics. 1986 Sep; 11(3):177-98.
Ayano G. Bipolar disorders and carbamazepine: pharmacokinetics, pharmacodynamics, therapeutic effects and indications of carbamazepine: review of articles. J Neuropsychopharmacol Ment Health. 2016; 1(112):2.
Published
Abstract Display: 544 
PDF Downloads: 507 PDF Downloads: 432 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.